Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Glenmark Pharma
Join Channel
Consolidated Standalone

Glenmark Pharma

₹1545 8.8 | 0.6%

Market Cap ₹43598 Cr.

Stock P/E -23.8

P/B 1.8

Current Price ₹1545

Book Value ₹ 848.6

Face Value 1

52W High ₹1830.1

Dividend Yield 0.16%

52W Low ₹ 766.7

Edit Ratio

Glenmark Pharma Research see more...

Overview Inc. Year: 1977Industry: Pharmaceuticals & Drugs

Glenmark Pharmaceuticals Ltd is a international pharmaceutical corporation. The Company is commonly engaged in the enterprise of developing, manufacturing and advertising and marketing of pharmaceutical products. It focuses on production products throughout therapeutic regions of breathing, dermatology and oncology. It is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments consist of India, North America, Europe and Rest of the world. It is centered on developing and advertising branded and universal formulations. Its products consist of FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral remedy to treat slight to moderate COVID-19. Its Ryaltris is a set-dose aggregate nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats signs and symptoms associated with seasonal, in addition to perennial allergic rhinitis. Its Remo is a sodium-glucose shipping-2 (SGLT2) inhibitor for the sort 2 diabetes.

Read More..

Glenmark Pharma Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Glenmark Pharma Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Glenmark Pharma Profit & Loss

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
Net Sales 2394 5204 6115 7989 5520 6305 6713 7568 8142 8221 7891
Other Income 67 85 117 148 180 476 607 396 615 986 1168
Total Income 2461 5289 6232 8137 5700 6780 7319 7964 8756 9207 9059
Total Expenditure 1898 3739 4350 5091 4419 4977 5408 5678 6453 6748 6649
Operating Profit 563 1550 1883 3047 1281 1803 1911 2287 2303 2459 2410
Interest 31 30 36 153 191 224 256 266 236 207 277
Depreciation 30 119 100 105 96 106 139 151 160 184 202
Exceptional Income / Expenses 0 -169 0 -236 0 345 19 74 430 -496 5070
Profit Before Tax 502 1232 1747 2553 994 1818 1535 1944 2337 1572 7001
Provision for Tax 68 224 262 412 128 330 180 294 340 363 1833
Profit After Tax 434 1008 1484 2141 866 1488 1355 1649 1998 1209 5167
Adjustments 0 0 0 0 148 134 0 0 0 0 0
Profit After Adjustments 434 1008 1484 2141 1014 1622 1355 1649 1998 1209 5167
Adjusted Earnings Per Share 16 37.1 52.6 75.9 30.7 52.7 48 58.5 70.8 42.8 183.1

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -4% 1% 5% 13%
Operating Profit CAGR -2% 2% 6% 16%
PAT CAGR 327% 46% 28% 28%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 83% 45% 35% 7%
ROE Average 25% 15% 14% 16%
ROCE Average 33% 18% 16% 18%

Glenmark Pharma Balance Sheet

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Shareholder's Funds 2906 4952 7366 9437 10391 11942 13226 14810 16739 17877 22971
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 2589 2686 2831 3131 3113 2572 2661 0
Other Non-Current Liabilities 360 930 279 400 -658 -624 389 1151 1413 2394 3287
Total Current Liabilities 1317 2659 3339 2899 2185 2281 2992 3934 4896 3992 5152
Total Liabilities 4584 8541 10984 15324 14604 16431 19738 23007 25619 26925 31410
Fixed Assets 449 1231 1438 1596 1699 1413 1612 1722 1752 1746 1756
Other Non-Current Assets 2444 3498 4322 6851 7030 9876 13099 14944 18009 20442 24109
Total Current Assets 1692 3813 5224 6877 5875 5141 5027 6340 5858 4735 5544
Total Assets 4584 8541 10984 15324 14604 16431 19738 23007 25619 26925 31410

Glenmark Pharma Cash Flow

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Opening Cash & Cash Equivalents 165 106 42 74 251 176 255 87 15 29 93
Cash Flow from Operating Activities 114 145 355 878 1124 2490 1579 1243 1216 1474 -495
Cash Flow from Investing Activities 217 -394 -1546 -2580 -1137 -2256 -1607 -1235 -897 -431 3197
Cash Flow from Financing Activities -385 -32 1223 1879 -62 -155 -139 -81 -305 -978 -2666
Net Cash Inflow / Outflow -54 -282 32 177 -75 79 -168 -73 14 64 35
Closing Cash & Cash Equivalent 106 42 74 251 176 255 87 15 29 93 128

Glenmark Pharma Ratios

# Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Earnings Per Share (Rs) 16 37.14 52.6 75.86 30.69 52.74 48 58.46 70.8 42.84 183.11
CEPS(Rs) 17.11 41.54 56.14 79.58 34.09 56.51 52.91 63.8 76.46 49.36 190.28
DPS(Rs) 2 2 2 2 2 2 2.5 2.5 2.5 2.5 2.5
Book NAV/Share(Rs) 107.15 182.54 261.01 334.38 367.9 422.85 468.25 524.29 593.12 633.48 813.92
Core EBITDA Margin(%) 20.34 27.71 28.46 35.81 19.86 21.05 19.43 22.7 18.77 16.04 13.22
EBIT Margin(%) 21.85 23.87 28.74 33.42 21.37 32.39 26.68 26.53 28.61 19.37 77.48
Pre Tax Margin(%) 20.58 23.3 28.16 31.53 17.93 28.84 22.86 23.34 25.98 17.12 74.53
PAT Margin (%) 17.79 19.06 23.93 26.44 15.62 23.61 20.18 19.8 22.21 13.16 55.01
Cash Profit Margin (%) 19.03 21.32 25.54 27.74 17.35 25.29 22.24 21.61 23.98 15.17 57.16
ROA(%) 9.93 15.35 15.2 16.27 5.79 9.59 7.49 7.72 8.22 4.6 17.72
ROE(%) 15.98 25.64 24.1 25.48 8.74 13.34 10.77 11.78 12.67 6.98 25.3
ROCE(%) 16.75 29.27 26.38 26.57 9.26 14.36 11.24 12.54 13.25 8.58 32.59
Receivable days 126.68 123.49 161.77 156.38 253.74 171.25 106.64 94.75 104.82 103.04 96.95
Inventory Days 29.98 32.7 50.15 47.64 74.27 58.54 47.54 35.06 34.77 40.58 43.38
Payable days 154.59 206.8 283.44 238.86 272.05 254.34 226.78 198.46 190.67 221.36 277.83
PER(x) 35.38 21.16 15.1 11.31 17.18 12.24 4.29 7.95 6.25 10.85 5.23
Price/Book(x) 5.28 4.31 3.04 2.57 1.43 1.53 0.44 0.89 0.75 0.73 1.18
Dividend Yield(%) 0.35 0.25 0.25 0.23 0.38 0.31 1.21 0.54 0.57 0.54 0.26
EV/Net Sales(x) 6.51 4.17 3.78 3.35 3.2 3.35 1.39 2.21 1.98 1.97 3.49
EV/Core EBITDA(x) 27.69 13.99 12.28 8.77 13.8 11.7 4.87 7.31 7 6.58 11.43
Net Sales Growth(%) 18.19 117.39 17.51 30.65 -30.9 14.21 6.47 12.74 7.58 0.97 -4.01
EBIT Growth(%) 25.79 136.77 41.29 51.76 -56.2 72.31 -12.29 23.37 16.47 -30.88 309.17
PAT Growth(%) 12.36 132.24 47.32 44.22 -59.55 71.89 -8.99 21.77 21.12 -39.49 327.48
EPS Growth(%) 12.21 132.18 41.64 44.21 -59.55 71.89 -8.99 21.77 21.12 -39.49 327.45
Debt/Equity(x) 0.12 0.08 0.11 0.29 0.29 0.26 0.27 0.25 0.22 0.18 0.03
Current Ratio(x) 1.28 1.43 1.56 2.37 2.69 2.25 1.68 1.61 1.2 1.19 1.08
Quick Ratio(x) 1.12 1.16 1.27 1.98 2.18 1.85 1.4 1.42 1 0.91 0.85
Interest Cover(x) 17.2 41.79 49.21 17.73 6.21 9.12 6.99 8.31 10.9 8.6 26.26
Total Debt/Mcap(x) 0.02 0.02 0.04 0.11 0.2 0.17 0.61 0.28 0.29 0.24 0.02

Glenmark Pharma Shareholding Pattern

# Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Promoter 46.65 46.65 46.65 46.65 46.65 46.65 46.65 46.64 46.65 46.65
FII 24.23 23.14 23.2 22.46 25.52 24.8 23.71 21.38 20.98 23.05
DII 10.5 10.94 10.73 10.44 9.15 10.35 10.95 13.4 13.96 13.25
Public 18.63 19.28 19.43 20.45 18.69 18.21 18.69 18.58 18.41 17.06
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has delivered good profit growth of 28% CAGR over last 5 years
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 46.65%.
  • Debtor days have increased from 221.36 to 277.83days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Glenmark Pharma News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!